Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Q: How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Q: Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs: 5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

68Ga-Dotatoc

Disc Medicine

nasopharyngeal carcinoma

phase 2 small molecule active

1 trial
68Ga-FAP-CHX

The First People's Hospital of Lianyungang

Tumor

phase 2 small molecule active

1 trial
68Ga-FAPI-46

The George Institute

Non-metastatic Pancreatic ductal adenocarcinoma

phase 2 small molecule active

1 trial
68Ga-FAPI-46

The George Institute

Triple-negative breast cancer (TNBC) patients at high risk of relapse

phase 2 small molecule active

1 trial
68Ga-FAPI-46

Istituto Gentili S.r.l.

oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT

phase 2 small molecule active

1 trial
68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket)

Istituto Gentili S.r.l.

Solid tumors

phase 2 other active

1 trial
68Ga-G21

The First People's Hospital of Lianyungang

Prostate Cancer (Adenocarcinoma)

phase 2 small molecule active

1 trial
68Ga-NODAGA-SNA006

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Cancer

phase 2 small molecule active

1 trial
68Ga-NY104 PET/CT

Peking University Third Hospital

Clear Cell Renal Cell Carcinoma

phase 2 other active

1 trial
68Ga-NY104 PET/CT

The First People's Hospital of Lianyungang

Clear Cell Renal Cell Carcinoma

phase 2 small molecule active

1 trial
6QC-ICG, Placebo for 6QC-ICG

Disc Medicine

Breast cancer

phase 2 small molecule active

1 trial
89Zr-Girentuximab

Telix Innovations

Clear Cell Renal Cell Carcinoma (ccRCC)

phase 2 small molecule active

1 trial
89Zr-Trastuzumab_IJB, Herceptin 150 mg powder for concentrate for solution for infusion, TRASTUZUMAB EMTANSINE

The George Institute

advanced/metastatic HER2-positive breast carcinoma

phase 2 small molecule active

1 trial
89Zr-girentuximab for PET/CT imaging of CAIX positive tumors

Telix Innovations

Cervical Cancer

phase 2 other terminated

1 trial
9-ING-41

ACTUATE THERAPEUTICS, INC.

Cancer

phase 2 small molecule active

1 trial
9-ING-41

ACTUATE THERAPEUTICS, INC.

Pancreatic Adenocarcinoma

phase 2 small molecule terminated

1 trial
9-ING-41

ACTUATE THERAPEUTICS, INC.

Salivary Gland Cancer

phase 2 small molecule active

1 trial
9-ING-41

ACTUATE THERAPEUTICS, INC.

Salivary Gland Carcinoma

phase 2 small molecule terminated

1 trial
A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Hoffmann-La Roche

Advanced or metastatic squamous cell carcinoma of the esophagus

phase 2 other active

1 trial
A Clinical Trial for Patients with Advanced Cancers

Corbus Pharmaceuticals Holdings

Advanced Solid tumour

phase 2 other active

1 trial
A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)

Merck Sharp and Dohme

Cancer – Solid Tumors : 1L NSCLC and all other advanced or metastatic solid tumors with KRAS alterations (KRAS mutation or KRAS amplification)

phase 2 other active

1 trial
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

Ningbo Cancer Hospital

Patients with a histilogically confirmed diagnosis of cervical squamous or adenosquamous carcinoma stage IB3 if N>=1 or II to IVA with any N stage according to FIGO 2018 and no evidence of metastatic disease (M0), without any prior anti-cancer treatment.

phase 2 other active

1 trial
A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301)

Tyra Biosciences

Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations

phase 2 other active

1 trial
A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

Lacuna Pharma Pty Ltd

Metastatic or locally advanced SST2-positive neuroendocrine neoplasms in adults

phase 2 other active

1 trial
A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of GSK5458514 PSMA targeting T cell engager alone or in combination with other anti-cancer agents in adult participants with metastatic castration-resistant prostate cancer (mCRPC)

GlaxoSmithKline

Neoplasms, Prostate

phase 2 other active

1 trial
A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

Bristol-Myers Squibb Australia Pty Ltd

Extensive-Stage Small Cell Lung Cancer

phase 2 other active

1 trial
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment

Shanghai Antengene Corporation Limited

Non-muscle invasive bladder cancer (NMIBC)

phase 2 other active

1 trial
A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

Wuhan Createrna Science and Technology Co., Ltd

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)"

phase 2 other active

1 trial
A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

GlaxoSmithKline

Neoplasms, Colorectal

phase 2 other active

1 trial
A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 years of age with CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)

SUTRO BIOPHARMA, INC.

Acute Myeloid Leukemia (AML)

phase 2 other active

1 trial
A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line metastatic urothelial carcinoma

Merck Sharp and Dohme

Advanced Urothelial Carcinoma

phase 2 other active

1 trial
A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid Tumors

Centessa Pharmaceuticals plc

Advanced solid tumors

phase 2 other active

1 trial
A Phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors

GlaxoSmithKline

Gastrointestinal Neoplasms

phase 2 other active

1 trial
A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences

Non-muscle invasive bladder cancer (NMIBC)

phase 2 other active

1 trial
A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression “(MAESTRA 1)”

Incyte

Ovarian Cancer

phase 2 other active

1 trial
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Therapeutics Inc

Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL

phase 2 other active

1 trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors

GlaxoSmithKline

Ovarian Neoplasms

phase 2 other active

1 trial
A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer

The George Institute

Patients with HER2Positive Advanced Breast Cancer

phase 2 other active

1 trial
A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastatic neuroendocrine prostate cancer

Novartis Pharmaceuticals

Metastatic neuroendocrine prostate cancer

phase 2 other active

1 trial
A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma

Hoffmann-La Roche

Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

phase 2 other active

1 trial
A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Hoffmann-La Roche

Previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)

phase 2 other active

1 trial
A Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed‑Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants with Locally Advanced, Recurrent or Metastatic Solid Tumors

Hoffmann-La Roche

Solid Tumors

phase 2 other active

1 trial
A Randomized, Open-Label, Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Hoffmann-La Roche

Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

phase 2 other active

1 trial
A clinical study of sacituzumab tirumotecan (sac-TMT) in people with bladder cancer (MK-2870-027)

Merck Sharp and Dohme

Intermediate-risk Non-muscle Invasive Bladder Cancer

phase 2 other active

1 trial
A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous nivolumab for advanced Hepatocellular carcinoma (HIPANIV)

The George Institute

Advanced hepatocellular carcinoma

phase 2 other active

1 trial
A phase II, monocentric, single arm trial evaluating the efficacy and safety of Pembrolizumab in combination with Lenvatinib in metastatic Uveal MElanoma patients

The George Institute

Metastatic uveal melanoma

phase 2 other active

1 trial
A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations

Pierre Fabre Medicament

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

phase 2 other active

1 trial
A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial (NICHOL TRIAL)

Fondazione Telethon ETS

Ovarian cancer

phase 2 other active

1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Quick answer

Top sponsors

68Ga-Dotatoc

68Ga-FAP-CHX

68Ga-FAPI-46

68Ga-FAPI-46

68Ga-FAPI-46

68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket)

68Ga-G21

68Ga-NODAGA-SNA006

68Ga-NY104 PET/CT

68Ga-NY104 PET/CT

6QC-ICG, Placebo for 6QC-ICG

89Zr-Girentuximab

89Zr-Trastuzumab_IJB, Herceptin 150 mg powder for concentrate for solution for infusion, TRASTUZUMAB EMTANSINE

89Zr-girentuximab for PET/CT imaging of CAIX positive tumors

9-ING-41

9-ING-41

9-ING-41

9-ING-41

A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

A Clinical Trial for Patients with Advanced Cancers

A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)

A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301)

A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of GSK5458514 PSMA targeting T cell engager alone or in combination with other anti-cancer agents in adult participants with metastatic castration-resistant prostate cancer (mCRPC)

A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 years of age with CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)

A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line metastatic urothelial carcinoma

A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid Tumors

A Phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors

A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression “(MAESTRA 1)”

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors

A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer

A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastatic neuroendocrine prostate cancer

A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma

A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed‑Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants with Locally Advanced, Recurrent or Metastatic Solid Tumors

A Randomized, Open-Label, Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

A clinical study of sacituzumab tirumotecan (sac-TMT) in people with bladder cancer (MK-2870-027)

A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous nivolumab for advanced Hepatocellular carcinoma (HIPANIV)

A phase II, monocentric, single arm trial evaluating the efficacy and safety of Pembrolizumab in combination with Lenvatinib in metastatic Uveal MElanoma patients

A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations

A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial (NICHOL TRIAL)

Frequently asked questions

Stay Ahead in Pharma